In addition, several other compounds with PLK4 inhibitory activity have been recently reported to show potent anticancer effects in breast cancer [123, 124, 128–132], ovarian cancer [43] and leukemia models [133]. The gene discussed is PLK4; the disease is ovarian cancer.